PARP1 and acute myeloid leukemia: However, our results also contraindicate the use of PARP inhibitors during 7+3 chemotherapy since olaparib exhibited antagonistic effects toward the killing of both M1/M2 and M4/M5 AML cancer cells by ara-C and idarubicin (Tables S2 and S3).